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Objectives
• Describe US contrast agents
– How they differ from MR/CT agents

• Review safety/administration
• Highlight major applications
• Describe some future applications

Ultrasound Contrast Agents
• Earliest agitated saline (Gramiak, 1968)
• Short half-life, trapped by pulmonary
capillaries
• Manufactured microbubbles from 2 – 7
microns
• Smaller than RBC, so can pass through
pulmonary circulation
Gramiak R, Shah PM. Echocardiography of
the aortic root.
Invest Radiol 1968;3:356–66
Quaia, E. Eur Radiol 2007; 17:1995-2008.

Microbubbles ex vivo

Definity (lipid shells)

Optison (protein shell) against RBCs

Wilson SR , Burns PN Microbubble-enhanced US in Body Imaging: What Role? Radiology
2010, 257, 24-39.

Chemical Content
• Microbubbles of gas in an encapsulating shell
• Air in a polysaccharide (Levovist)
• perflurocarbon or sulfur hexachloride stabilized
by a thin shell (Definity, Lumason, Imagent-lipid)
(Optison-protein)

• Most only intravascular
• Some drugs have hepatic (Levovist, Sonazoid)
or splenic (Lumason) phase
Stewart and Sidhu; The British Journal of Radiology, 79 (2006), 188–194

Mode of Administration
• .5-2cc IV- bolus (preferred) or infusion
• Enhances blood signal 500-1000x
• Lasts 5 min (avg.) with bolus- longer with
infusion.
• Bubbles rupture, gas exhaled via lungs, shell
metabolized by the body
• Major risk is anaphylaxis- at rate of 1/7000
(U.S.) to 1/10,000 (Europe) less than that of
CT, comparable to most antibiotics.
Wilson SR , Burns PN Microbubble-enhanced US in Body Imaging: What Role? Radiology
2010, 257, 24-39.

Is it Safe?
• U of R has administered >10,000 doses without a
serious adverse event
• Definity does cause mild back pain-self limited- in
1/200 patients.
• October 2007 FDA issued “black box” warning due to
a few serious events (possible anaphylaxis)
worldwide (4 deaths in the US) in patients having
cardiac events- No cause and effect established
• Black Box modified 9 months later

Retrospective Results
• Kusnetsky reviews 18,671 hospitalized
patients undergoing echocardiography
• No effect of contrast on mortality
• Patients receiveing CEUS exams did better
than those who did not get agent

Kusnetzky LL , Khalid A , Khumri TM , Moe TG , Jones PG , Main ML . Acute
mortality in hospitalized patients undergoing echocardiography with and without
an ultrasound contrast agent: results in 18,671 consecutive studies . J Am Coll
Cardiol 2008 ; 51 ( 17 ): 1704 – 1706 .

Current FDA recommendations
• Assess all patients for the presence of any
condition precluding contrast administration
(allergy)
• In patients with pulmonary hypertension or
unstable cardiopulmonary conditions, monitor
VS, ECG and O2sat for 30 minutes after
Optison or Definity or Lumason
• Have resuscitation equipment available

US Contrast in Radiology
• Approved for Liver in UK, Canada, Europe and
Japan since early 2000’s
• 2016- Lumason approved for liver imaging in
the US for lesion characterization.
April 4, 2016 -- The long wait is over. The U.S. Food and Drug
Administration (FDA) for the first time has approved the use of an
ultrasound contrast agent for radiology applications, giving the nod to
Lumason from Bracco Diagnostics to be used for focal liver lesions.
Lumason was known previously in the U.S. as SonoVue, and it received
initial FDA approval in October 2014 for use in patients with suboptimal
echocardiograms to opacify the left ventricular chamber and to improve the
delineation of the left ventricular endocardial border. The agent is still
offered by Bracco under the SonoVue brand outside of the U.S.

Current Contraindications
• Known allergy to US contrast
• Patients with right to left or bidirectional
cardiac shunts
– Recent MI
– Severe Heart Failure
– Consider Cardiology Consult

• Not for intra-arterial injection

How do they work?
• Unlike blood cells (same size) which we do not
see, we see US contrast because
– Bubbles contain gas which reflects the sound
– Bubbles oscillate in the 3-5MHz range (same as we
use for abdominal US) creating echoes of their own,
independent of those transmitted by the machine.
– These independent echoes are a multiple of the
inciting frequency, and are known as harmonics
– We can selectively receive the harmonic frequency
and see only the bubbles signal, suppressing
background.

Liver Imaging with Contrast
• Liver image (MIP) 11
sec after injection.
• Note the number
and small size of the
vessels (down to 5th
order branches) seen
only with contrast.
• Deficit area is a
hemangioma
Wilson SR , Burns PN Microbubble-enhanced US in Body Imaging: What Role? Radiology
2010, 257, 24-39.

Liver Mass Characterization
• Benign lesions: Hemangioma, FNH, equivalent
to CT or MR- prolonged delayed enhancement
• Adenoma has some overlap with HCC- soft
washout
• Metastases and HCC equivalent to CT/MR
– Better for early wash-in and washout due to high
frame rate and long observation times (up to 20
minutes)
– Difficulty with deep lesions, blind spots under
diaphragm and behind ribs

Why does this work?
• Liver has dual blood supply
– 30% from HA-arrives in 15-30 sec from injection
– 70% from PV-arrives 50-70sec from injection

• Malignant Tumors supplied by HA’s
– enhance more than background liver, in HAP
– In PV phase , background liver enhances more
than the malignant tumor (early for mets and
CholangioCa, later for HCC

• Benign tumors have HA supply but stay
enhanced in PV phase

Wilson et AJR 2006

Figure 1: Schematic shows the typical enhancement patterns of common benign and malignant lesions in the cirrhotic liver.
RN = regenerative nodule, DN = dysplastic nodule, AP = arterial phase, PVP = portal venous phase, LP = late phase.
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CEUS in the Kidney
• Solid Mass characterization- equivalent to CT
for Clear cell RCC, and superior for Papillary
(showed minimal flow better than CT) (1)
• Bosniak II lesions seen with CEUS (31 patients,
accuracy 74% by CT, 90% by US, US tended to
upstage lesions (thicker septae)- (2)
(1)Tamai H, Takiguchi Y, Oka M, et al. Contrast-enhanced ultrasonography in the diagnosis of
solid renal tumors. J Ultrasound Med 2005;24(12):1635–1640
(2)Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic renal masses based
on Bosniak classification: comparison of CT and contrast-enhanced US. Eur J Radiol
2007;61(2):310–314.
Wilson SR , Burns PN Microbubble-enhanced US in Body Imaging: What Role? Radiology
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Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic
renal masses based on Bosniak classification: comparison of CT and
contrast-enhanced US. Eur J Radiol 2007;61(2):310–314.

Number of Septae US >CT

Park BK, Kim B, Kim SH, Ko K, Lee HM, Choi HY. Assessment of cystic
renal masses based on Bosniak classification: comparison of CT and
contrast-enhanced US. Eur J Radiol 2007;61(2):310–314.

Prospective CEUS vs CT Complex Cysts
• 40 patients with complex cystic masses
detected by CT
• 3 readers
• Path outcome or 24 mo F/U
• 21 RCCs, 9 complex cysts, 2MCNs, 8 simple
cysts
• CEUS accuracy 80-83%, vs 63-75% CT
• Non-enhanced US accuracy only 30%
Quaia E, Bertolotto M, Cioffi V, et al. Comparison of Contrast-Enhanced Sonography with
Unenhanced Sonography and Contrast-Enhanced CT in the Diagnosis of Malignancy in
Complex Cystic Renal Masses AJR 2008; 191:1239-1249

Patient with Indeterminate Mass (MR)
who cannot get CT or MR contrast

Patient with Indeterminate Mass on
MR who cannot get CT or MR contrast

Pre Contrast

Post Contrast

Patient with CRF suspected Mass on
CT and unenhanced US.

Patient with CRF suspected Mass on
CT and unenhanced US.

Patient with Indeterminate Mass on
Contrast CT- 86 yo female

US Contrast 2nd bolus combined phases

Vascular/Interventional
Applications
• Hepatic/Renal transplants- confirm vascular
patency
• Endografts- diagnose leaks/monitor therapy
• Monitor ablations

IMPROVED HA VISUALIZATION
WITH US CONTRAST
• 8/72 no flow on CDUS
• 6 flow on CEUS
(Optison .5ml)
– confirmed with angio or
nl f/u US.

• 2 no flow, angiography
confirmed
• US sensitivity rose from
.91 to 1.0 (p<.014)
Benjamin K. Hom, BS, Ruchi Shrestha, MD, Suzanne L. Palmer, MD, Michael D. Katz, MD, R.
Rick Selby, MD, Zhanna Asatryan, BA, Jabali K. Wells, BS and Edward G. Grant, MD Prospective
Evaluation of Vascular Complications after Liver Transplantation: Comparison of
Conventional and Microbubble Contrast-enhanced US Radiology 2006;241:267-274

AAA ENDOGRAFT SURVEILLANCE AND
THERAPY: ROLE OF US
• CT preferred to assess graft anatomy, and to dx stent
migration, leaks
• CEUS equally effective to CT and DSA for endoleaks
in small groups of selected patients: 20(a), 30(b) and
24(c) but less effective in overall literature review (d)
• Occasionally better for delayed and/or small leaks
• US potentially useful to guide therapy

a)

Bendick PJ. Bove PG. Long GW. Zelenock GB. Brown OW. Shanley CJ. Efficacy of ultrasound scan contrast agents in the noninvasive follow-up of aortic stent
grafts. Journal of Vascular Surgery. 37(2):381-5, 2003 Feb.

b)

Napoli V. Bargellini I. Sardella SG. Petruzzi P. Cioni R. Vignali C. Ferrari M. Bartolozzi C. Abdominal aortic aneurysm: contrast-enhanced US for missed endoleaks
after endoluminal repair. Radiology. 233(1):217-25, 2004 Oct.

c)

Dill-Macky MJ, Aortic Endografts: Detecting Endoleaks Using Contrast-enhanced Ultrasound. Ultrasound Quarterly. 22:49-52, 2006

d)

Sun Z, Diagnostic value of color duplex ultrasonography in the follow-up of endovascular repair of abdominal aortic aneurysm. Journal of vascular and
interventional radiology [1051-0443] 2006 vol:17 iss:5 pg:759 -64

84 YO DIABETIC WITH ENDOGRAFT
AORTIC REPAIR

endoleak AAA 5cm
attempted
angiographic rx.
8 mo later persistent
endoleak AAA
5.6cm

2 yrs later AAA 6.3cm with
renal insufficiency –angio same
time shows no endoleak

Gray scale and color Doppler show AAA
Only contrast study shows endoleak

POST THROMBIN

After initial1000u thrombin injection the leak is no longer seen
with repeat contrast bolus (Definity .75cc/bolus)

Contrast guided and monitored RFA of Renal Tumors

Contrast-Enhanced UltrasoundGuided Radiofrequency Ablation of
Renal Tumors
Lackey, Logan II; Peterson, Cynthia;
Barr, Richard G.
Ultrasound Quarterly. 28(4):269274, December 2012.
doi:
10.1097/RUQ.0b013e318274de66
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Other
Applications
• Bowel (IBD,
Ischemia)
• Cystoscopy
(VCUG)
• Trauma
• Ovary,
Prostate?
CEUS in Crohn’s Disease Ripolles et al Insights Imaging Dec 2011

Conclusions
• US Contrast a powerful tool to enhance US diagnosis
• Primary use in characterizing focal lesions (liverWilson et al)
• Useful in assessing ablation margins (Liver, kidneyeuropean studies)
• Vascular agent for intra-abdominal vessels
(transplants, vascular stents)
• Applications in bowel (Wilson), ovary, prostate?
• Great potential use in patients who cannot receive
CT or MR contrast due to allergy, renal function or
location (interventional, OR, etc)

unknowns

63 yo with cirrhosis- HCC screen
Hepatitis C, GFR 30, pacemaker

• 1.7cm
• Internal flow
• Dx?

67 F with lung carcinoid and
Indeterminate mass left K

10-24 HU

40 HU

67 F with lung carcinoid and
Indeterminate mass left K, neg bx

21 HU

42 HU

